Effectiveness and safety of pegylated liposomal doxorubicin versus epirubicin as neoadjuvant or adjuvant chemotherapy for breast cancer: a real-world study

Jin Zhang1*, Hongchuan Jiang2, Jian Zhang3, Guoqiang Bao4, Guoqiang Zhang5, Haibo Wang6 and Xi Wang7

Abstract

Background: Pegylated liposomal doxorubicin (PLD) is an improved formulation of doxorubicin with comparable effectiveness but significantly lower cardiotoxicity than conventional anthracycline. This study aimed to evaluate the real-world effectiveness and safety of PLD versus epirubicin as neoadjuvant or adjuvant treatment for breast cancer.

Methods: Clinical data of invasive breast cancer patients who received neoadjuvant or adjuvant chemotherapy with PLD or epirubicin were retrospectively collected. Propensity score matching (PSM) was performed to reduce the risk of selection bias. The molecular typing of these patients included Luminal A, Luminal B, HER2-positive, and basal-like/triple-negative. The primary outcome was pathological complete response (pCR) rate for neoadjuvant chemotherapy and 3-year disease-free survival (DFS) rate for adjuvant chemotherapy. Noninferiority was suggested if the lower limit of the 95% CI for the 3-year DFS rate difference was greater than $-10%$. The secondary outcome was adverse reactions.

Results: A total of 1213 patients were included (neoadjuvant, $n=274$; adjuvant, $n=939$). pCR (ypT0/Tis ypN0) rates of patients who received neoadjuvant chemotherapy were 11.6% for the PLD group and 7.0% for the epirubicin group, but the difference was not statistically significant ($P=0.4578$). The 3-year DFS rate of patients who received adjuvant chemotherapy was 94.9% [95%CI, 91.1–98.6%] for the PLD group and 95.4% [95%CI, 93.0–97.9%] for the epirubicin group ($P=0.5684$). Rate difference between the two groups and its 95% CI was $-0.55 [-5.02, 3.92]$. The lower limit of the 95% CI was $-5.0% > -10.0%$, suggesting that PLD is not be inferior to epirubicin in adjuvant chemotherapy for breast cancer. The incidences of myelosuppression, decreased appetite, alopecia, gastrointestinal reactions, and cardiotoxicity were lower in the PLD group than in the epirubicin group, while the incidence of nausea was higher in the PLD group.

Conclusions: In the neoadjuvant and adjuvant treatment of breast cancer, effectiveness is similar but toxicities are different between the PLD-containing regimen and epirubicin-containing regimen. Therefore, further study is warranted to explore PLD-based neoadjuvant and adjuvant chemotherapy for breast cancer.

*Correspondence: zhangjintjmuch1@163.com
1 Third Department of Breast Surgery, Tianjin Medical University Cancer Institute and Hospital; National Clinical Research Center for Cancer; Key Laboratory of Cancer Prevention and Therapy; Clinical Research Center for Cancer, Tianjin 300060, China
Full list of author information is available at the end of the article
Background
Breast cancer is the most common malignancy in women worldwide. According to the 2018 statistics of the International Agency for Research on Cancer (IARC) of the World Health Organization, there were 2.08 million new cases of breast cancer and 620,000 breast cancer-related deaths in the world, which accounted for 24.2 and 15% of all malignancies and malignancy-related deaths in women, respectively [1]. Preoperative neoadjuvant chemotherapy and postoperative adjuvant chemotherapy can effectively reduce the risk of recurrence and improve the cure rate of early and locally advanced breast cancer patients [2, 3].

Anthracycline-based chemotherapy is a common neoadjuvant and adjuvant therapy for breast cancer patients. The recommended anthracycline drugs include doxorubicin and epirubicin [4]. Anthracyclines have significant effectiveness in breast cancer, but they often cause alopecia, myelosuppression, and gastrointestinal reactions. In addition, anthracycline-induced cardiotoxicity was reported to be closely associated with the cumulative dose of the drug [5], and can also occur at a low dose, and can be acute, chronic, and delayed, most of which occur in the first year of treatment [6]. The risk factors for anthracycline-induced cardiotoxicity include being < 5 or > 65 years of age, past or current chest irradiation, history of heart diseases, or the presence of cardiovascular risk factors [7]. Furthermore, concurrent anti-HER2 therapies can increase the risk of cardiotoxicity with anthracyclines [8–10]. Anthracycline-related cardiotoxicities are often progressive and irreversible, leading to ventricular dysfunction, heart failure, and arrhythmia [11].

Pegylated liposomal doxorubicin (PLD) is a liposomal formulation of doxorubicin with comparable effectiveness but markedly lower cardiotoxicity than conventional anthracycline [12], thus allowing a higher cumulative dose of the drug. The National Comprehensive Cancer Network guidelines recommended PLD as the first-line treatment for advanced breast cancer [4]. A phase II clinical trial compared the effectiveness of PLD versus epirubicin in combination with vinorelbine as the first-line treatment for metastatic breast cancer. The study found that there were no significant differences in ORR, PFS, and OS between the two groups. Furthermore, while cardiotoxicity was not reported in the PLD group, one (1.9%) patient reported arrhythmia and two (3.7%) patients had over 20% decrease in LVEF in the epirubicin group [13]. Several research groups have explored the effectiveness and safety of PLD as neoadjuvant/adjuvant therapy for breast cancer. Song et al. carried out a phase I/II trial of PLD neoadjuvant therapy for breast cancer. The results showed that the maximum tolerated dose of PLD was 40 mg/m², and the breast pCR rate was 18.8% (95% CI, 11.5–26.0%) with no significant decrease in LVEF [14, 15]. Another multicenter randomized-controlled trial confirmed that PLD and trastuzumab combination therapy significantly lowered the incidence of cardiotoxicity compared with doxorubicin plus cyclophosphamide followed by paclitaxel plus trastuzumab [16]. This real-world study aimed to compare the effectiveness and safety of PLD to epirubicin as neoadjuvant or adjuvant treatment for breast cancer patients.

Methods
Data source and study population
The medical records of breast cancer patients who received PLD (CSPC Ouyi Pharmaceutical Co., Ltd., Shijiazhuang, China) or epirubicin-based neoadjuvant (January 2014 to January 2018) or adjuvant treatment (June 2014 to June 2016) were retrospectively collected. Inclusion criteria: 18–70 years old; female; histologically confirmed invasive breast cancer; received PLD or epirubicin neoadjuvant chemotherapy or adjuvant chemotherapy; LVEF ≥ 50%. Exclusion criteria: occult breast cancer patients; used two or more anthracyclines during neoadjuvant or adjuvant chemotherapy; previously received other chemotherapy regimens. After screening, the patients were divided into the neoadjuvant chemotherapy group and adjuvant chemotherapy group according to their treatment stage and then into the PLD group and epirubicin group according to the drug regimen.

The study was approved by the Ethics Research Committee of Tianjin Cancer Hospital.

Trial Registration: ClinicalTrials.gov, Identifier: NCT03983096.

Molecular subtyping
The expression statuses of ER, PR, HER2, and Ki67 were detected by immunohistochemical staining to determine the molecular subtyping. ER and PR were considered positive when more than 1% of the tumor cells exhibited positive staining. For HER2 staining, a score of 3+ was considered positive; a specimen with a score of 2+ was tested by fluorescence in situ hybridization analysis.
The standard threshold value of Ki67 was 20%. If \( \geq 20\% \) it was considered to be high Ki67 expression, otherwise low Ki67 expression. In 2013, the St. Gallen International Breast Cancer Conference defined the molecular classification of breast cancer [17]. When ER and/or PR+, HER2- and Ki67 < 20%, it was defined as Luminal A. Luminal B was divided into two situations. When ER+ and/or PR < 20%, HER2- and Ki67 ≥ 20%, it was defined as HER2-negative (B1 type). When ER+ and/or PR+, HER2 overexpression and Ki67 ≥ 20%, it was defined as HER2-positive type (B2 type). The characteristics of HER2-positive type were HER2+ as HER2-negative (B1 type). When ER+, ER- and PR-, Basal-like/triple-negative features were HER2-, ER- and PR-.

Cardiotoxicity
Cardiotoxicity was defined as abnormal results of cardiac function in clinical evaluation, including decreased ventricular ejection fraction (LVEF ≤ 50%; LVEF lower than ≥10% of the baseline value), congestive heart failure, arrhythmia, etc. [7]. Cardiotoxicity was not graded.

Statistical analysis
The primary outcome for neoadjuvant chemotherapy was the total pathological complete response (pCR) rate (tpCR, ypT0/Tis ypN0), which was defined as the absence of residual invasive cancer cells or only carcinoma in situ in the primary and metastatic lymph nodes after surgery. The primary outcome for adjuvant chemotherapy was the 3-year disease-free survival (DFS) rate. DFS referred to the time from the first postoperative chemotherapy to recurrence, metastasis, or death. The secondary outcome was the incidence of adverse reactions.

When the baseline characteristics of the eligible patients were balanced, the eligible case data were used for statistical analysis. Otherwise, propensity score-matching (PSM) was conducted to reduce the selection bias between the PLD and epirubicin groups. The variables included in PSM were age, lymph node metastasis, tumor size, and molecular typing.

All statistical tests were two-sided with a significance level of \( \alpha = 0.05 \). The 3-year DFS rate of adjuvant chemotherapy was compared between the two groups using the chi-square test or Fisher’s exact test. According to the conditions of the patients included, this study conducted subgroup analyses of the main study outcomes for the neoadjuvant chemotherapy and adjuvant chemotherapy population. Factors such as menopausal status (premenopausal or postmenopausal), tumor size (T1 or T2), lymph node metastasis (N0, N1, N2, and N3), clinical stage (II or IIIA), ER status (positive or negative), PR status (positive or negative), HER2 status (positive or negative), and Ki-67 expression level (<20% or ≥ 20%) were considered for the subgroup analyses.

For safety analysis, the number and incidence of adverse reactions in the PLD group and epirubicin group were counted.

Results
Patients
The clinical data of 1309 breast cancer patients who were diagnosed and treated in seven hospitals in China between January 2014 and January 2018 were retrospectively reviewed. A total of 1213 patients met the selection criteria (patient selection flowchart shown in Fig. 1), including 274 neoadjuvant chemotherapy patients and 939 adjuvant chemotherapy patients.

The common chemotherapy regimens included PLD or epirubicin combined with cyclophosphamide (C), PLD or epirubicin combined with C followed by a taxane (T), T followed by PLD or epirubicin combined with C, PLD or epirubicin combined with T, PLD or epirubicin combined with T and C, and PLD or epirubicin combined with C and 5-fluorouracil (Table 1). The dose of treatment was 30–40 mg/m² for PLD and 60–75 mg/m² for epirubicin.

Among the 274 patients who received neoadjuvant chemotherapy, 195 (71.2%) had evaluable effectiveness (79 patients discontinued neoadjuvant treatment due to unknown reasons and lacked the results of pCR), including 65 (65/195, 33.3%) patients who received PLD-containing regimen, and 130 (130/195, 66.7%) patients who received epirubicin-containing regimen. The baseline characteristics of the patients, including age < 35 \((P = 0.0353)\), tumor size \((P = 0.0452)\), and lymph node metastasis \((P = 0.0109)\), were not evenly distributed across the PLD and epirubicin groups before PSM. After one-to-one PSM, there were 43 patients in each group, and the baseline characteristics of the two groups were balanced (Table 2). The median age was 49 (25–70) and 48 (27–67) years, the number of premenopausal patients was 20 (52.6%) and 27 (64.3%), and the number of patients with Ki67 ≥ 20% were 22 (75.9%) and 18 (72.0%) for the PLD group and epirubicin group, respectively.
Among the patients who received adjuvant chemotherapy, 292 (31.1%) patients received a PLD-containing regimen, and 647 (68.9%) patients received an epirubicin-containing regimen. The baseline characteristics of the patients, namely age < 35 ($P = 0.0262$) and lymph node metastasis ($P = 0.0046$), were not evenly distributed between the two groups before PSM. After PSM (1:2), there were 201 patients in the PLD group and 402 patients in the epirubicin group, and the baseline characteristics were balanced between the two groups (Table 3). The median age was 49 (25–69) years, and 50 (23–70) years, the number of premenopausal patients was 105 (56.8%) and 228 (58.6%), and the number of patients with $\text{Ki67} \geq 20\%$ was 125 (77.2%) and 242 (72.2%), respectively.

**Effectiveness**

**Pathological complete response**

Before PSM, the postoperative pathology of 195 evaluable patients who received neoadjuvant chemotherapy showed slightly higher tpCR in the PLD group (9, 13.9%) than in the epirubicin group (12, 9.2%), but the
The difference was not statistically significant ($P = 0.3270$). Breast pCR (bpCR, ypT0/Tis) was also higher in the PLD group (16, 24.6%) than in the epirubicin group (20, 15.4%), but the difference was not statistically significant ($P = 0.1173$) (Table 4).

After PSM, tpCR (11.6% vs. 7.0%, $P = 0.4578$) and bpCR (25.6% vs. 14.0%, $P = 0.1758$) were also comparable between the PLD group and epirubicin group (Table 4).

Given that there were fewer cases in the neoadjuvant chemotherapy group, the subgroup analyses (menopausal status, tumor size, N status, clinical stage, ER status, PR status, HER2 status, and Ki-67 expression level) could not be performed.

### Three-year DFS

Before PSM, the 3-year DFS rate of the 939 eligible patients who received adjuvant chemotherapy was not significantly different between the PLD (96.0, 95% CI = 93.2−98.7%) and epirubicin groups (95.1, 95% CI = 93.1−97.1%) ($P = 0.6516$) (Fig. 2A and Table 5).

After PSM, the 3-year DFS rate was also not significant different between the PLD (94.9, 95% CI = 91.1−98.6%) and epirubicin groups (95.4, 95% CI = 93.0−97.9%) ($P = 0.5684$) (Fig. 2B). The rate difference between the

| Table 2 | Baseline characteristics of neoadjuvant chemotherapy patients before and after PSM |
|---------|----------------------------------------------------------------------------------|
| **Characteristics** | **Before PSM (N = 185)** | **Epirubicin group (N = 130)** | **After PSM (N = 86)** | **Epirubicin group (N = 43)** |
| **PLD group (N = 65)** | **Epirubicin group (N = 43)** | **P value** | **PLD group (N = 65)** | **Epirubicin group (N = 43)** | **P value** |
| Age (year), n (%) | 0.0353 | 1.0000 | 0.1919 | 0.4812 |
| < 35 | 15 (23.1%) | 15 (11.5%) | 10 (23.3%) | 10 (23.3%) |
| ≥ 35 | 50 (76.9%) | 115 (88.5%) | 33 (76.7%) | 33 (76.7%) |
| Age (year), Median (range) | 46 (25.70) | 50 (27.67) | 49 (36–60) | 48 (36–58) |
| Menopausal status, n (%) | 0.1082 | 0.2903 | 0.0109 | 0.8122 |
| Premenopausal | 38 (58.5%) | 64 (49.2%) | 20 (46.5%) | 27 (62.8%) |
| Postmenopausal | 22 (33.9%) | 62 (47.7%) | 18 (41.9%) | 15 (34.9%) |
| Missing | 5 (7.7%) | 4 (3.1%) | 5 (11.6%) | 1 (2.3%) |
| Nodal status, n (%) | 0.0452 | 0.9719 | 0.0592 | 0.5642 |
| N0 | 22 (33.9%) | 40 (30.8%) | 16 (37.2%) | 12 (27.9%) |
| N1 | 21 (32.3%) | 25 (19.2%) | 14 (32.6%) | 16 (37.2%) |
| N2 | 10 (10.8%) | 30 (23.1%) | 7 (16.3%) | 9 (20.9%) |
| N3 | 7 (10.8%) | 33 (25.4%) | 6 (14.0%) | 6 (14.0%) |
| Missing | 5 (12.3%) | 1 (1.5%) | 8 (19.6%) | 1 (2.3%) |
| Tumor size, n (%) | 0.0452 | 0.9719 | 0.0592 | 0.5642 |
| T1 | 14 (21.5%) | 43 (33.1%) | 14 (32.6%) | 12 (27.9%) |
| T2 | 30 (46.2%) | 42 (32.3%) | 24 (55.8%) | 26 (60.5%) |
| T3 | 6 (2.7%) | 15 (11.5%) | 3 (7.0%) | 3 (7.0%) |
| T4 | 2 (3.1%) | 13 (10.0%) | 2 (4.7%) | 2 (4.7%) |
| Missing | 15 (23.1%) | 17 (13.1%) | 8 (18.6%) | 5 (11.6%) |
| Molecular subtype, n (%) | 0.0452 | 0.9719 | 0.0592 | 0.5642 |
| Luminal A | 10 (15.4%) | 18 (13.9%) | 8 (18.6%) | 5 (11.6%) |
| Luminal B | 30 (46.2%) | 56 (43.1%) | 23 (53.5%) | 20 (46.5%) |
| HER2+ | 6 (9.2%) | 13 (10.0%) | 4 (9.3%) | 2 (4.7%) |
| BASAL-LIKE | 3 (4.6%) | 14 (10.8%) | 1 (2.3%) | 3 (7.0%) |
| Missing | 16 (24.6%) | 29 (22.3%) | 7 (16.3%) | 13 (30.2%) |
| Ki-67 expression, n (%) | 0.5803 | 0.7468 | 0.5803 | 0.7468 |
| < 20% | 8 (12.3%) | 16 (12.3%) | 7 (16.3%) | 7 (16.3%) |
| ≥ 20% | 34 (52.3%) | 52 (40.0%) | 22 (51.2%) | 18 (41.9%) |
| Missing | 23 (35.4%) | 62 (47.7%) | 14 (32.6%) | 18 (41.9%) |
two groups and its 95% CI was $-0.55 \pm [5.02, 3.92]$. In the exploratory noninferiority analysis, the lower limit of the 95% CI was $-5.0\% > -10.0\%$, suggesting that the effectiveness of PLD is be not inferior to that of epirubicin (Table 5).

After PSM, the 3-year DFS rate was analyzed by subgroups according to the menopause status (premenopausal or postmenopausal), tumor size (T1 or T2), lymph node metastasis (N0, N1, N2 or N3), clinical stage (II or IIIA), ER (positive or negative), PR (positive or negative), HER-2 (positive or negative), Ki-67 expression (<20% or ≥20%), and histological grade (grade II or III). 3-year DFS rate was higher in premenopausal, T2, N2, stage II, Ki-67 ≥20% patients in the PLD group than in the epirubicin group (Fig. 3).

### Table 3 Baseline characteristics of adjuvant chemotherapy patients before and after PSM

| Characteristics                        | Before PSM (N = 939) | Epirubicin group (N = 647) | PLD group (N = 292) | Epirubicin group (N = 647) | P value | PLD group (N = 201) | Epirubicin group (N = 402) | P value |
|----------------------------------------|----------------------|---------------------------|---------------------|---------------------------|---------|---------------------|---------------------------|---------|
| Age (year), n (%)                      | 0.0262               |                           |                     |                           | 1.0000  |                     |                           | 0.7495  |
| < 35                                   | 14 (4.8%)            | 58 (9.0%)                 | 10 (5.0%)           | 20 (5.0%)                 |         |                     |                           |         |
| ≥ 35                                   | 278 (95.2%)          | 589 (91.0%)               | 191 (95.0%)         | 382 (95.0%)               |         |                     |                           |         |
| Age (year), Median (range)             | 48 (25,70)           | 49 (23,70)                | 49 (42–56)          | 50 (44–56)                | 0.8529  | 49 (42–56)          | 50 (44–56)                | 0.7495  |
| Menopausal status, n (%)               | 0.2343               |                           |                     |                           | 0.6739  |                     |                           |         |
| Premenopausal                          | 115 (39.4%)          | 242 (37.4%)               | 105 (52.2%)         | 228 (56.7%)               |         |                     |                           |         |
| Postmenopausal                         | 153 (52.4%)          | 384 (59.4%)               | 80 (39.8%)          | 161 (40.1%)               |         |                     |                           |         |
| Missing                                | 24 (8.2%)            | 21 (3.3%)                 | 16 (8.0%)           | 13 (3.2%)                 |         |                     |                           |         |
| Histological grade, n (%)             | 0.9289               |                           |                     |                           | 0.4268  |                     |                           |         |
| I                                      | 3 (1.0%)             | 9 (1.4%)                  | 2 (1.0%)            | 9 (2.2%)                  |         |                     |                           |         |
| II                                     | 121 (41.4%)          | 294 (45.4%)               | 95 (47.3%)          | 206 (51.2%)               |         |                     |                           |         |
| III                                    | 77 (26.4%)           | 181 (28.0%)               | 52 (25.9%)          | 95 (23.6%)                |         |                     |                           |         |
| Missing                                | 91 (31.2%)           | 163 (25.2%)               | 52 (25.9%)          | 92 (22.9%)                |         |                     |                           |         |
| Nodal status, n (%)                    | 0.0046               |                           |                     |                           | 0.9049  |                     |                           |         |
| N0                                     | 141 (48.3%)          | 284 (43.9%)               | 103 (51.2%)         | 202 (50.3%)               |         |                     |                           |         |
| N1                                     | 80 (27.4%)           | 184 (28.4%)               | 69 (34.3%)          | 202 (50.3%)               |         |                     |                           |         |
| N2                                     | 22 (7.5%)            | 89 (13.8%)                | 19 (9.5%)           | 36 (9.0%)                 |         |                     |                           |         |
| N3                                     | 12 (4.1%)            | 58 (9.0%)                 | 10 (5.0%)           | 26 (6.5%)                 |         |                     |                           |         |
| Missing                                | 37 (12.7%)           | 32 (5.0%)                 | 0 (0.0%)            | 0 (0.0%)                  |         |                     |                           |         |
| Tumor size, n (%)                      | 0.3915               |                           |                     |                           | 0.4213  |                     |                           |         |
| T1                                     | 130 (44.5%)          | 268 (41.4%)               | 97 (48.3%)          | 182 (45.3%)               |         |                     |                           |         |
| T2                                     | 105 (36.0%)          | 277 (42.8%)               | 81 (40.3%)          | 179 (44.5%)               |         |                     |                           |         |
| T3                                     | 7 (2.4%)             | 16 (2.3%)                 | 7 (3.5%)            | 8 (2.0%)                  |         |                     |                           |         |
| T4                                     | 1 (0.3%)             | 5 (0.8%)                  | 1 (0.5%)            | 1 (0.3%)                  |         |                     |                           |         |
| Missing                                | 49 (16.8%)           | 81 (12.5%)                | 15 (7.5%)           | 32 (8.0%)                 |         |                     |                           |         |
| Molecular subtype, n (%)              | 0.2054               |                           |                     |                           | 0.7747  |                     |                           |         |
| Luminal A                              | 56 (19.2%)           | 91 (14.1%)                | 40 (19.9%)          | 76 (18.9%)                |         |                     |                           |         |
| Luminal B                              | 141 (48.3%)          | 317 (49.0%)               | 126 (62.7%)         | 261 (64.9%)               |         |                     |                           |         |
| HER2+                                  | 32 (11.0%)           | 76 (11.8%)                | 20 (10.0%)          | 43 (10.7%)                |         |                     |                           |         |
| BASAL-LIKE                             | 17 (5.8%)            | 51 (7.9%)                 | 15 (7.5%)           | 22 (5.5%)                 |         |                     |                           |         |
| Missing                                | 46 (15.8%)           | 112 (17.3%)               | 0 (0.0%)            | 0 (0.0%)                  |         |                     |                           |         |
| Ki-67 expression, n (%)               | 0.3344               |                           |                     |                           | 0.2419  |                     |                           |         |
| < 20%                                  | 65 (22.3%)           | 122 (18.9%)               | 37 (18.4%)          | 93 (23.1%)                |         |                     |                           |         |
| ≥ 20%                                  | 174 (59.6%)          | 388 (60.0%)               | 125 (62.2%)         | 242 (60.2%)               |         |                     |                           |         |
| Missing                                | 53 (18.2%)           | 137 (21.2%)               | 39 (19.4%)          | 67 (16.7%)                |         |                     |                           |         |

PLD, pegylated liposomal doxorubicin
A total of 1213 patients (362 in the PLD group and 851 in the epirubicin group) who received neoadjuvant chemotherapy or adjuvant chemotherapy were included in the safety analysis. According to the medical records of the patients, the incidence of adverse reactions was lower in the PLD group (15.2%) than in the epirubicin group (18.1%). The common adverse reactions were myelosuppression, decreased appetite, cardiotoxicity, and gastrointestinal reactions (Table 6). The incidence of cardiotoxicity was higher in the epirubicin group (6.6%) than in the PLD group (2.2%). The main manifestations of cardiotoxicity were abnormal ST segment (ECG), sinus tachycardia. There were no cardiac failure-related records. In addition, the incidences of myelosuppression, decreased appetite, alopecia, and gastrointestinal reaction were lower, but the incidence of nausea was higher in the PLD group than in the epirubicin group.

**Discussion**

Anthracycline plays an important role in the neoadjuvant and adjuvant treatment of breast cancer, and the common anthracycline-based chemotherapy regimens include AC, AC-T, TAC, and AT. Doxorubicin was the first anthracycline drug to be used in the treatment of breast cancer, and the common cardiotoxicity associated with doxorubicin is cardiac dysfunction [18]. Pegylated liposome doxorubicin (PLD) has unique pharmacokinetic and pharmacodynamic properties due to its altered formulation, which can effectively reduce drug exposure in normal tissue and thus minimize toxicity while ensuring treatment effectiveness [12]. pCR (ypT0/is or ypT0/is ypN0) is a standard effectiveness outcome of neoadjuvant therapy for breast cancer.

### Table 4 pCR of neoadjuvant chemotherapy

| Safety                                                                 |   |
|----------------------------------------------------------------------|---|
| A total of 1213 patients (362 in the PLD group and 851 in the epirubicin group) who received neoadjuvant chemotherapy or adjuvant chemotherapy were included in the safety analysis. According to the medical records of the patients, the incidence of adverse reactions was lower in the PLD group (15.2%) than in the epirubicin group (18.1%). The common adverse reactions were myelosuppression, decreased appetite, cardiotoxicity, and gastrointestinal reactions (Table 6). The incidence of cardiotoxicity was higher in the epirubicin group (6.6%) than in the PLD group (2.2%). The main manifestations of cardiotoxicity were abnormal ST segment (ECG), sinus tachycardia. There were no cardiac failure-related records. In addition, the incidences of myelosuppression, decreased appetite, alopecia, and gastrointestinal reaction were lower, but the incidence of nausea was higher in the PLD group than in the epirubicin group. |   |

#### Table 4 pCR of neoadjuvant chemotherapy

| pCR                  | PLD group n (%) | Epirubicin group n (%) | P value |
|----------------------|-----------------|------------------------|---------|
| Before PSM, n        | 65              | 130                    |         |
| bpCR                 | 16 (24.6%)      | 20 (15.4%)             | 0.1173  |
| tpCR                 | 9 (13.9%)       | 12 (9.2%)              | 0.3270  |
| After PSM, n         | 43              | 43                     |         |
| bpCR                 | 11 (25.6%)      | 6 (14.0%)              | 0.1758  |
| tpCR                 | 5 (11.6%)       | 3 (7.0%)               | 0.4578  |

*PLD* Pegylated liposomal doxorubicin, *bpCR* Total pathological complete response, *tpCR* Breast pathological complete response

**Fig. 2** Kaplan-Meier curves of disease-free survival (DFS) of among patients who received adjuvant chemotherapy. (A) DFS before PSM, (B) DFS after PSM. PLD, pegylated liposomal doxorubicin

### Table 5 Three-year DFS rate of adjuvant chemotherapy

| Safety                                                                 |   |
|----------------------------------------------------------------------|---|
| A total of 1213 patients (362 in the PLD group and 851 in the epirubicin group) who received neoadjuvant chemotherapy or adjuvant chemotherapy were included in the safety analysis. According to the medical records of the patients, the incidence of adverse reactions was lower in the PLD group (15.2%) than in the epirubicin group (18.1%). The common adverse reactions were myelosuppression, decreased appetite, cardiotoxicity, and gastrointestinal reactions (Table 6). The incidence of cardiotoxicity was higher in the epirubicin group (6.6%) than in the PLD group (2.2%). The main manifestations of cardiotoxicity were abnormal ST segment (ECG), sinus tachycardia. There were no cardiac failure-related records. In addition, the incidences of myelosuppression, decreased appetite, alopecia, and gastrointestinal reaction were lower, but the incidence of nausea was higher in the PLD group than in the epirubicin group. |   |

#### Table 5 Three-year DFS rate of adjuvant chemotherapy

| PLD group | Epirubicin group | P value | Rate difference (PLD group-epirubicin group), 95%CI |
|-----------|-----------------|---------|---------------------------------------------------|
| Before PSM, n | 292              | 647     | 0.6516                                          | 0.85 [−2.54, 4.24] |
| 3-year DFS, % [95%CI] | 96.0% [93.2, 98.7] | 95.1% [93.1, 97.1] | 0.6516 | 0.85 [−2.54, 4.24] |
| After PSM, n  | 201              | 402     | 0.5684                                          | −0.55 [−5.02, 3.92] |
| 3-year DFS, % [95%CI] | 94.9% [91.1, 98.6] | 95.4% [93.0, 97.9] | 0.5684 | −0.55 [−5.02, 3.92] |

*PLD* Pegylated liposomal doxorubicin
Pooled analysis showed that patients who achieved pCR have improved survival [19, 20]. Previous studies have shown that the pCR of breast cancer patients after neoadjuvant chemotherapy is about 1–68% [21–23], varying according to the cancer subtype: 1% for luminal A, 8% for luminal B, 38% for HER2-positive, and 23% for triple-negative [23]. However, the clinical stage, HER2 status, Ki-67 expression, HR status, and other factors may affect the effectiveness of neoadjuvant therapy. Several studies have shown that PLD-containing neoadjuvant therapy is effective for the treatment of breast cancer [15, 24–28]. A retrospective study comparing the effectiveness and safety of PLD to epirubicin as neoadjuvant treatment for breast cancer demonstrated that patients in the PLD group had a similar clinical response rate (76.7% vs. 75.6%, \( P = 0.317 \)) and pCR rate (16.3% vs. 11.6%, \( P = 0.056 \)) as those in the epirubicin group [29]. Yao et al. also found that PLD-containing neoadjuvant chemotherapy had comparable effectiveness (18.5% pCR rate) as epirubicin in the treatment of locally advanced breast cancer [22]. Adjuvant therapy is an important treatment for early breast cancer patients as it significantly reduces the risk of recurrence and improves patient survival [30–32]. Anthracycline-based chemotherapy is also a common adjuvant therapy [33, 34]. In the NEAT/BR9601 study, the seven-year follow-up results showed that compared with cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) alone, CMF followed by epirubicin significantly improved the 5-year relapse-free survival (RFS) (78%
followed, and the results will be updated. A follow-up was only 3 years. The patients are still being followed up, adjuvant therapy for breast cancer. Nevertheless, the long-term benefit of PLD is still uncertain since the diagnosis and treatment data analyzed in this study were collected from only seven hospitals.

Abbreviations

PLD: Pegylated liposomal doxorubicin; PSM: Propensity score matching; pCR: Pathological complete response; DFS: Disease-free survival; IARC: International Agency for Research on Cancer; CMF: Cyclophosphamide, methotrexate and 5-fluorouracil; RFS: Relapse-free survival; CI: Confidence interval.

Acknowledgments

Not applicable.

Authors’ contributions

JZ, HJ, JZ, GB, GZ, HW, XW participated in the following works: conception, design, acquisition of data, analysis of data, interpretation of data, drafting of manuscripts and critical revision of manuscripts. All authors have read and approved the final manuscript.

Availability of data and materials

The datasets used and/or analyzed during the present study are available from the corresponding author on reasonable request.

Declarations

Ethics approval and consent to participate

The present study was approved by the Administration Ethics Committee of Tianjin Medical University Cancer Institute and Hospital and conducted in accordance with the Principles of Helsinki Declaration. Patient consent was exempt because of the retrospective nature of the study.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Author details

1. Third Department of Breast Surgery, Tianjin Medical University Cancer Institute and Hospital; National Clinical Research Center for Cancer; Key Laboratory of Cancer Prevention and Therapy; Clinical Research Center for Cancer, Tianjin 300060, China. 2. Department of Breast Surgery, Beijing Chaoyang Hospital, Capital Medical University, Beijing 100020, China. 3. Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China. 4. General Surgery Department, Tangdu Hospital, The Fourth Military Medical University, Xi’an 710038, China. 5. Department of Breast Surgery, Harbin Medical University Cancer Hospital, Harbin 150040, China. 6. Department of Breast Surgery, The Affiliated Hospital of Qingdao University, Qingdao 266071, China. 7. Department of Breast Surgery, Sun Yat-sen University Cancer Center, Guangzhou 510060, China.

Received: 23 June 2021 Accepted: 8 November 2021 Published online: 06 December 2021

References

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424.

2. Reinert T, Gonçalves R, Ellis MJ. Current status of neoadjuvant endocrine therapy in early stage breast cancer. Curr Treat Options in Oncol. 2018;19:23.

3. Jones SE, Moon TE, Bonadonna G, Valagussa P, Rivkin S, Buzdar A, et al. Comparison of different trials of adjuvant chemotherapy in stage

Conclusions

In this study, we used a matched case-control design with stringent matching criteria to compare the effectiveness and safety of PLD vs. epirubicin as neoadjuvant or adjuvant chemotherapy in breast cancer patients who received the treatment within the same period. Patients who received adjuvant chemotherapy were followed up for at least 3 years to obtain their long-term survival benefit data. However, the long-term benefit of PLD is still
21. van Ramshorst MS, van Werkhoven E, Honkoop AH, Dezentjé VO, Oving IM, Mandjes IA, et al. Toxicity of dual HER2-blockade with pertuzumab added to anthracycline versus non-anthracycline containing chemotherapy as neoadjuvant treatment in HER2-positive breast cancer: the TRAINE-2 study. Breast. 2016;29:153–9.

22. Haque W, Verma V, Hatch S, Suzanne Klimberg V, Brian Butler E, Teh BS. Response rates and pathologic complete response by breast cancer molecular subtype following neoadjuvant chemotherapy. Breast Cancer Res Treat. 2018;170:539–67.

23. Yao J, Pan S, Fan X, Jiang X, Yang Y, Jin J, et al. Pegylated liposomal doxorubicin as neoadjuvant therapy for stage I-II locally advanced breast cancer. J Chemother. 2020;32:202–7.

24. Tampaki EC, Tampakis A, Aliferis CE, Krikidis D, Patsaiti A, Kontos M, et al. Efficacy and safety of neoadjuvant treatment with bevacizumab, liposomal doxorubicin, cyclophosphamide and paclitaxel combination in locally/regionally advanced, HER2-negative, grade 3 at premenopausal status breast cancer: a phase II study. Clin Drug Invest. 2018;38:639–48.

25. Gil-Gil MJ, Bellet M, Morales S, Ojeda B, Manso L, Mesa C, et al. Pegylated liposomal doxorubicin plus cyclophosphamide followed by paclitaxel as primary chemotherapy in elderly or cardiotoxicity-prone patients with high-risk breast cancer: results of the phase II CAPRICE study. Breast Cancer Res Treat. 2015;151:597–606.

26. Tuxen MK, Cold S, Tange UB, Balbieve E, Nielsen DL. Phase II study of neoadjuvant pegylated liposomal doxorubicin and cyclophosphamide ± trastuzumab followed by docetaxel in locally advanced breast cancer. Acta Oncol. 2014;53:1440–5.

27. Artioli G, Moccioni S, Borgato L, Cappetta A, Bozza F, Zavagno G, et al. Phase II study of neoadjuvant gemcitabine, pegylated liposomal doxorubicin, and docetaxel in locally advanced breast cancer. Anticancer Res. 2013;33:3817–21.

28. Dong M, Luo L, Yin X, Lu X., Shen J, Jiang Z, et al. Comparable efficacy and less toxicity of pegylated liposomal doxorubicin versus epirubicin for neoadjuvant chemotherapy of breast cancer: a case-control study. Oncol Targets Ther. 2018;11:4247–52.

29. Fuji T, Le Du F, Xiao L, Kogawa T, Barcenas CH, Alvarez RH, et al. Effectiveness of an adjuvant chemotherapy regimen for early-stage breast cancer: a systematic review and Network Meta-analysis. JAMA Oncol. 2015;1:1311–8.

30. Bines J, Earl H, Buraid AC, Saad ED. Anthracyclines and taxanes in the neo/adjuvant treatment of breast cancer: does the sequence matter? Ann Oncol. 2014;25:1079–85.

31. Anampa J, Makower D, Sparano JA. Progress in adjuvant chemotherapy for breast cancer: an overview. BMC Med. 2015;13:195.

32. Ding W, Li Z, Wang C, Dai J, Ruan G, Tu C. Anthracycline versus nonanthracycline adjuvant chemotherapy for early breast cancer: A systematic review and meta-analysis. Medicine (Baltimore). 2018;97:e12908.

33. Tarokh DJ, Palmeni FM, Perez EA. Anthracyclines vs nonanthracycline adjuvant therapy for breast cancer. Oncology (Williston Park). 2004;18:1367–76 discussion:1378, 1381.

34. Early HM, Hiller L, Dunn JA, Vallier AL, Bowden SJ, Jordan SD, et al. Adjuvant epirubicin followed by cyclophosphamide, methotrexate and fluorouracil (CMF) vs CMF in early breast cancer: results with over 7 years median follow-up from the neo/adjuvant phase III NEAT/BR0601 trials. Br J Cancer. 2012;107:1257–67.

35. Lu YC, Ou-Yang FJ, Hsieh CM, Chang KJ, Chen DR, Tu CW, et al. Pegylated liposomal doxorubicin as adjuvant therapy for stage III–IV operable breast cancer. In Vivo. 2016;30:159–63.

36. Yang FO, Hsu NC, Moi SH, Lu YC, Hsieh CM, Chang KJ, et al. Efficacy and toxicity of pegylated liposomal doxorubicin-based chemotherapy in early-stage breast cancer: a multicenter retrospective case-control study. Asia Pac J Clin Oncol. 2018;14:1918–203.

37. Sparano JA, Mahkson AN, Semiglazov VF, Tulandin SA, Balashova OD, Bondarenko IN, et al. Pegylated liposomal doxorubicin plus docetaxel significantly improves time to progression without additive cardiotoxicity compared with docetaxel monotherapy in patients with previously treated neoadjuvant-adjuvant anthracycline therapy: results from a randomized phase III study. J Clin Oncol. 2009;27:4522–9.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.